Table 2.

Efficacy of Sotorasib Therapy.^*

Variable	Phase 1 (N = 12)	Phase 2 (N = 26)	Combined Phase 1–2 (N = 38)
Best overall response — no. (%)†
Confirmed complete response	0	0	0
Confirmed partial response	3 (25)	5 (19)	8 (21)
Stable disease	6 (50)	18 (69)	24 (63)
Progressive disease	2 (17)	3 (12)	5 (13)
Could not be evaluated	0	0	0
Not assessed	1 (8)	0	1 (3)
Percentage of patients with objective response (95% CI) — %	25 (6–57)	19 (7–39)	21 (10–37)
Percentage of patients with disease control (95% CI) — %‡	75 (43–95)	89 (70–98)	84 (69–94)
Median time to objective response (range) — mo§	1.4 (1.3–1.5)	2.8 (1.3–5.6)	1.5 (1.3–5.6)
Median duration of response (95% CI) — mo§¶	—	—	5.7 (1.6–NE)

^*An objective response was defined as a complete or partial response. NE denotes could not be evaluated.

^†The best overall response was determined by blinded independent central review.

^‡Disease control was defined as an objective response or stable disease.

^§The median time to objective response and the median duration of response were calculated for the patients who had a confirmed objective response.

^¶The median duration of response (Kaplan–Meier estimates) is not provided for individual phases because of the small number of patients.